Why Reliable References Matter
Medicine information should be based on reliable and authoritative sources.
For prescription medicines such as baricitinib, regulatory product information is particularly important because it defines approved indications, dosage recommendations, contraindications, warnings, monitoring requirements and safety information for a specific jurisdiction.
U.S. Regulatory Information
The U.S. Food and Drug Administration’s prescribing information and DailyMed labeling provide important information concerning Olumiant and baricitinib.
The current DailyMed record identifies baricitinib tablets, indications, dosage, warnings, adverse reactions, interactions and clinical pharmacology.
European Medicines Agency
The European Medicines Agency provides the European Public Assessment Report and product information for Olumiant.
European regulatory information is particularly useful for understanding authorized uses in:
- Rheumatoid arthritis
- Atopic dermatitis
- Alopecia areata
- Juvenile idiopathic arthritis
Regulatory Differences
An important principle when researching medicines is that regulatory authorization differs by jurisdiction.
An indication authorized in Europe should not automatically be presented as a U.S. indication.
Similarly, a U.S. indication should not automatically be represented as authorized in every other country.
Product-Specific Sources
For Barinib 2 mg and Barigen 4 mg, product-specific manufacturer and regulatory information should be obtained from:
- Product packaging
- Official product documentation
- Applicable national medicine databases
- Authorized manufacturer documentation
- Appropriate regulatory authorities
The supplied product brief identifies the products but does not independently document every product-specific detail.
Clinical Literature
Peer-reviewed clinical research can provide additional information about:
- Efficacy
- Safety
- Long-term treatment
- Patient populations
- Comparative treatment
- Disease-specific outcomes
However, clinical trials should be interpreted in context.
A study involving a particular population does not necessarily apply to every patient.
Reference Hierarchy
For treatment decisions, a reasonable source hierarchy includes:
- Current official prescribing information
- National regulatory authority information
- Recognized regulatory assessment reports
- Peer-reviewed clinical evidence
- Established professional medical organizations
- Educational secondary sources
Why Dates Matter
Medicine information changes.
Regulatory labels can be revised after new safety information, new clinical evidence or new approved indications become available.
The current U.S. DailyMed record for Olumiant reflects labeling revised in June 2026, demonstrating why outdated webpages should not be relied upon indefinitely.
References Used for This Website
Primary sources include:
- U.S. DailyMed prescribing information for Olumiant/baricitinib
- U.S. regulatory medicine information
- European Medicines Agency Olumiant information
- Applicable clinical evidence concerning baricitinib
- Official product information where available
Product-Specific Limitation
The reference medicine information should not be presented as proof of the identity, manufacturer or regulatory authorization of every product containing baricitinib.
Barinib and Barigen should be verified independently through appropriate product documentation.
Final Reference Principle
Reliable medical content requires both accurate information and appropriate context.
A reference should support the exact claim being made, and the date and jurisdiction of that reference should be considered.